SCHEMBL4462865

SCHEMBL4462865

CCN1CC2(CCC2)Cc2cc(OC)c(C)c(C)c21

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
AKT1 P31749 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MITF O75030 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4468214 0.86 KDM4E (0.32) ALDH1A1KDM4E
SCHEMBL4463581 0.81
SCHEMBL4482479 0.77 CYP2D6 (0.33) ALDH1A1
SCHEMBL4466453 0.76 CNR1 (0.32) ALDH1A1
SCHEMBL4464426 0.74 NPC1 (0.38) ALDH1A1KDM4E
SCHEMBL5316270 0.72 JAK2 (0.34) ALDH1A1KDM4E
SCHEMBL4467811 0.72 ALDH1A1 (0.40) ALDH1A1KDM4E
SCHEMBL4469389 0.68
SCHEMBL4474004 0.68 RAB9A (0.41) ALDH1A1KDM4EMAPK1
SCHEMBL4462214 0.67 ATM (0.40) ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 ALDH1A1 169/4885AKT1 1241/4885KDM4E 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.